CN111892539B - 异长叶烯酮基己内酰胺衍生物及其制备方法和应用 - Google Patents
异长叶烯酮基己内酰胺衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN111892539B CN111892539B CN202010770691.9A CN202010770691A CN111892539B CN 111892539 B CN111892539 B CN 111892539B CN 202010770691 A CN202010770691 A CN 202010770691A CN 111892539 B CN111892539 B CN 111892539B
- Authority
- CN
- China
- Prior art keywords
- cinnamoyl
- methanobenzo
- hexahydro
- tetramethyl
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- -1 Isolongifolenone caprolactam derivative Chemical class 0.000 title claims abstract description 18
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 7
- JZFSLMDLIPKTAO-UHFFFAOYSA-N 1,3-dihydroazepin-2-one Chemical class O=C1CC=CC=CN1 JZFSLMDLIPKTAO-UHFFFAOYSA-N 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 238000005917 acylation reaction Methods 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 4
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical class ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000010933 acylation Effects 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract description 2
- 238000006555 catalytic reaction Methods 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 18
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- LGSKOQUJWNADCQ-BONVTDFDSA-N (-)-isolongifolen-9-one Chemical compound C([C@@H](C1)C2(C)C)C[C@]31C2=CC(=O)CC3(C)C LGSKOQUJWNADCQ-BONVTDFDSA-N 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- GLBIKPKWQDIQCJ-UHFFFAOYSA-N 3-(4-fluorophenyl)prop-2-enoyl chloride Chemical compound FC1=CC=C(C=CC(Cl)=O)C=C1 GLBIKPKWQDIQCJ-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000004192 longifolene derivatives Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- ARGVABDJPRRAQI-VOTSOKGWSA-N (e)-3-(4-methylphenyl)prop-2-enoyl chloride Chemical compound CC1=CC=C(\C=C\C(Cl)=O)C=C1 ARGVABDJPRRAQI-VOTSOKGWSA-N 0.000 description 1
- SCNRDAIXZJFMEX-UHFFFAOYSA-N 3-(3-chlorophenyl)prop-2-enoyl chloride Chemical compound ClC(=O)C=CC1=CC=CC(Cl)=C1 SCNRDAIXZJFMEX-UHFFFAOYSA-N 0.000 description 1
- YLABICHHIYWLQM-UHFFFAOYSA-N 3-(4-bromophenyl)prop-2-enoyl chloride Chemical compound ClC(=O)C=CC1=CC=C(Br)C=C1 YLABICHHIYWLQM-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- OLTVTFUBQOLTND-UHFFFAOYSA-N tris(2-methoxyethoxy)-methylsilane Chemical compound COCCO[Si](C)(OCCOC)OCCOC OLTVTFUBQOLTND-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了异长叶烯酮基己内酰胺衍生物及其制备方法和应用。本发明以异长叶烯酮基己内酰胺衍生物为原料,以肉桂酰氯衍生物为酰化试剂,在碱的催化作用下发生酰化反应,制得3‑肉桂酰基‑5,5,9,9‑四甲基‑4,5,6,7,8,9‑六氢‑5a,8‑桥亚甲基苯并[d]吖庚因‑2(3H)‑酮类化合物。本申请通过实验证实,3‑肉桂酰基‑5,5,9,9‑四甲基‑4,5,6,7,8,9‑六氢‑5a,8‑桥亚甲基苯并[d]吖庚因‑2(3H)‑酮类化合物对人乳腺癌细胞MCF‑7具有较好的抑制活性,具有潜在的制备抗肿瘤药物的应用价值。
Description
技术领域
本发明属于药物化学和药物治疗学领域,具体涉及一种异长叶烯酮基己内酰胺衍生物及其制备方法和应用。
背景技术
异长叶烯酮(Isolongifolenone)是天然产物松节油主要成分长叶烯的重要衍生物,其结构中含有α,β-不饱和酮,具有众多的生物活性,如抗炎、抗病毒、抗真菌、抗肿瘤等。近年来,有研究表明异长叶烯酮及其衍生物可以增加肿瘤细胞内的ROS水平,从而杀伤肿瘤细胞。但是,异长叶烯酮及其衍生物的抗肿瘤活性低,需要高剂量给药才能获得所需药效,进而会造成毒性积累,限制其进一步的开发。
环内酰胺及其衍生物具有多种药理活性,如抗炎、抗真菌、抗血小板凝聚、镇痛等,是一种具有药用价值的化学物质。近年来研究表明,环内酰胺及其衍生物可抑制肿瘤细胞的增殖、侵袭、转移和促进细胞凋亡。机制研究表明:环内酰胺能通过选择性诱导肿瘤细胞中的活性氧(ROS)上调,不影响正常细胞的ROS,从而达到选择性杀死肿瘤细胞的功能;此外,环内酰胺还可通过激活P53信号通路或通过降低NF-κB的表达来抑制肿瘤细胞的增殖。因此,结合异长叶烯酮的α,β-不饱和酮的结构优势,开发异长叶烯酮基己内酰胺衍生物,并应用于抗肿瘤活性研究具有重要意义。
发明内容
针对现有技术的不足,本发明所要解决的技术问题在于提供一种由天然产物长叶烯衍生物5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为原料,制得的具有潜在抗肿瘤活性并且低毒的3-肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮类化合物。本发明所要解决的另一技术问题是提供一种3-肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮类化合物的制备方法。本发明还要解决一技术问题是提供3-肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮类化合物在制备抗肿瘤药物中的应用。
为了解决上述技术问题,本发明采用的技术方案为:
异长叶烯酮基己内酰胺衍生物,为3-肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮类化合物,其结构通式为:
其中R为:2-甲基苯基、2-甲氧基苯基、2-三氟甲基苯基、3-氟苯基、3-氯苯基、3-甲基苯基、3-三氟甲基苯基、4-氟苯基、4-氯苯基、4-溴苯基、4-三氟甲基苯基、4-甲基苯基等基团。
异长叶烯酮基己内酰胺衍生物的制备方法为:
以5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为原料,以肉桂酰氯为酰化试剂,在碱的催化作用下发生酰化反应,制得制得3-肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮类化合物;反应式如下:
具体包括如下步骤:
(1)将0.5mmol的5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮、2~6mmol三乙胺和5~15mL无水二氯甲烷加至配有搅拌器和温度计的100mL三口烧瓶中,在冰浴下将0.5~1mmol肉桂酰氯滴加至反应体系中,滴加结束后移去冰浴,反应温度慢慢升至室温并继续反应3~4h,采用TLC跟踪反应进程;
(2)反应结束后,向反应液中加入10~30mL蒸馏水,用二氯甲烷萃取三次,合并有机层,经水洗、无水硫酸钠干燥、过滤、浓缩、乙酸乙酯/石油醚重结晶,得到3-肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮类化合物。
3-肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮类化合物在制备抗肿瘤药物中的应用。
所述的肿瘤为人乳腺癌细胞MCF-7。
有益效果:与现有技术相比,本发明的突出优点如下:
(1)异长叶烯酮廉价易得,来源丰富,有利于工业化生产;
(2)3-肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮类化合物具有合成工艺简单,选择性和产率较高,符合绿色化学要求;
(3)3-肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮类化合物与阳性对照紫杉醇相比,对人乳腺癌细胞MCF-7具有较好的抑制活性,具有潜在的抗肿瘤药物制备的应用价值。
具体实施方式
下面结合具体实施例对本发明做进一步说明。
实施例1
3-(4′-氟)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物1)的制备:
在50mL的单口烧瓶中依次加入5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(0.5mmol)、三乙胺(5mmo1)和无水二氯甲烷(20mL),冰浴下滴加对氟肉桂酰氯(0.5mmol),滴加结束后室温反应4h,TLC检测反应完全,加水,二氯甲烷萃取,合并,浓缩,柱层析纯化(石油醚:乙酸乙酯=4∶1),得到白色固体粉末,收率74.5%。1HNMR(600MHz,CDCl3)δ:7.64(d,J=15.5Hz,1H),7.54(dd,J=8.6,5.5Hz,2H),7.21(d,J=15.6Hz,1H),7.04(t,J=8.6Hz,2H),5.74(s,1H),4.11(d,J=14.4Hz,1H),3.56(d,J=14.4Hz,1H),1.97(s,1H),1.89-1.91(m,1H),1.78-1.83(m,1H),1.72(d,J=7.9Hz,1H),1.53-1.57(m,1H),1.40(d,J=10.1Hz,1H),1.28-1.38(m,1H),1.17(s,3H),1.09(s,3H),1.06(s,3H),0.96(s,3H);13C NMR(151MHz,CDCl3)δ:176.74,170.04,169.81,141.33,130.07,130.01,121.86,115.87,115.73,114.14,63.74,49.13,46.07,45.52,37.68,34.32,28.88,28.79,25.37,24.81,24.21,23.09。
实施例2
3-(4′-甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物2)的制备:
制备方法同实施例1,以对甲基肉桂酰氯替换对氟肉桂酰氯,产物3-(4′-甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率73.8%。1H NMR(600MHz,CDCl3)δ:7.68(d,J=15.5Hz,1H),7.45(d,J=8.1Hz,2H),7.25(d,J=15.5Hz,1H),7.16(d,J=7.9Hz,2H),5.74(s,1H),4.10(d,J=14.5Hz,1H),3.56(d,J=14.5Hz,1H),2.35(s,3H),1.96(s,1H),1.88-1.93(m,1H),1.77-1.82(m,1H),1.71(d,J=10.2,1H),1.51-1.57(m,1H),1.39(d,J=10.1Hz,1H),1.27-1.32(m,1H),1.16(s,3H),1.09(s,3H),1.05(s,3H),0.96(s,3H);13C NMR(151MHz,CDCl3)δ:176.42,170.11,170.02,142.90,140.15,132.53,129.44,128.25,120.99,114.25,63.70,49.14,46.07,45.47,37.68,34.34,28.90,28.76,25.37,24.82,24.21,23.12,21.46。
实施例3
3-(4′-氯)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物3)的制备:
制备方法同实施例1,以对氯肉桂酰氯替换对氟肉桂酰氯,产物3-(4′-氯)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率77.8%。1H NMR(600MHz,CDCl3)δ:7.64(d,J=15.6Hz,1H),7.51(d,J=8.5Hz,2H),7.34(d,J=8.5Hz,2H),7.27(d,J=15.7Hz,1H),5.76(s,1H),4.14(d,J=14.5Hz,1H),3.58(d,J=14.4Hz,1H),1.98(m,1H),1.91-1.95(m,1H),1.80-1.84(m,1H),1.74(d,J=10.1,1H),1.60-1.53(m,1H),1.43(d,J=10.2,1H),1.30-1.35(m,1H),1.19(s,3H),1.12(s,3H),1.08(s,3H),0.98(s,3H);13C NMR(151MHz,CDCl3)δ:176.86,170.04,169.71,141.04,135.58,133.81,129.37,128.96,122.68,114.08,63.75,49.12,46.06,45.54,37.67,34.31,28.87,28.79,25.36,24.81,24.22,23.08。
实施例4
3-(4′-三氟甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物4)的制备:
制备方法同实施例1,以对三氟甲基肉桂酰氯替换对氟肉桂酰氯,产物3-(4′-三氟甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率70.5%。1H NMR(600MHz,CDCl3)δ:7.66(d,J=2.8Hz,1H),7.64(d,J=4.6Hz,2H),7.60(d,J=8.3Hz,2H),7.33(d,J=15.6Hz,1H),5.75(s,1H),4.13(d,J=14.4Hz,1H),3.56(d,J=14.4Hz,1H),1.97(s,1H),1.89-1.94(m,1H),1.89-1.94(m,1H),1.72(d,J=10.2,1H),1.53-1.58(m,1H),1.41(d,J=10.2Hz,1H),1.28-1.33(m,1H),1.17(s,3H),1.10(s,3H),1.06(s,3H),0.96(s,3H);13C NMR(151MHz,CDCl3)δ:177.27,170.17,169.60,140.38,138.87,128.40,125.80,125.77,124.79,114.09,63.92,49.25,46.19,45.72,37.81,34.42,28.99,28.94,25.48,24.94,24.35,23.19。
实施例5
3-(2′-甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物5)的制备:
制备方法同实施例1,以邻甲基肉桂酰氯替换对氟肉桂酰氯,产物3-(2′-甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率75.6%。1H NMR(600MHz,CDCl3)δ:7.96(d,J=15.4Hz,1H),7.62(d,J=8.3Hz,1H),7.23(t,J=7.4Hz,1H),7.15-7.21(m,3H),5.75(s,1H),4.11(d,J=14.4Hz,1H),3.57(d,J=14.4Hz,1H),2.45(s,3H),1.96(s,1H),1.89-1.91(m,1H),1.78-1.82(m,1H),1.72(d,J=10.1,1H),1.52-1.58(m,1H),1.40(d,J=10.2Hz,1H),1.28-1.33(m,1H),1.16(s,3H),1.09(s,3H),1.06(s,3H),0.97(s,3H);13C NMR(151MHz,CDCl3)δ:176.51,170.12,169.99,140.12,137.62,134.17,130.61,129.56,126.75,126.17,123.11,114.19,63.72,49.17,46.07,45.48,37.69,34.34,28.89,28.77,25.37,24.82,24.21,23.11,19.84。
实施例6
3-(3′-氟)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物6)的制备:
制备方法同实施例1,以间氟肉桂酰氯替换对氟肉桂酰氯,产物3-(3′-氟)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率77.2%。1H NMR(600MHz,CDCl3)δ:7.61(d,J=15.5Hz,1H),7.30-7.33(m,2H),7.25(d,J=15.4Hz,2H),7.01-7.06(m,1H),5.74(s,1H),4.12(d,J=14.4Hz,1H),3.55(d,J=14.4Hz,1H),1.97(s,1H),1.89-1.94(m,1H),1.78-1.83(m,1H),1.72(d,J=10.2,1H),1.53-1.58(m,1H),1.40(d,J=10.2Hz,1H),1.28-1.33(m,1H),1.17(s,3H),1.09(s,3H),1.06(s,3H),0.96(s,3H);13C NMR(151MHz,CDCl3)δ:176.92,170.02,169.63,140.96,140.94,130.22,124.19,124.17,123.47,116.65,116.51,114.45,114.30,114.05,63.75,49.11,46.06,45.56,37.66,34.30,28.86,28.80,25.36,24.81,24.22,23.07。
实施例7
3-(3′-氯)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物7)的制备:
制备方法同实施例1,以间氯肉桂酰氯替换对氟肉桂酰氯,产物3-(3′-氯)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率73.3%。1H NMR(600MHz,CDCl3)δ:7.58(d,J=15.5Hz,1H),7.55(s,1H),7.41(dt,J=6.9,1.7Hz,1H),7.32-7.27(m,2H),7.27(s,1H),5.75(s,1H),4.12(d,J=14.4Hz,1H),3.55(d,J=14.4Hz,1H),1.97(s,1H),1.89-1.94(m,1H),1.78-1.83(m,1H),1.72(d,J=10.1,1H),1.53-1.59(m,1H),1.41(d,J=10.2Hz,1H),1.28-1.33(m,1H),1.17(s,3H),1.10(s,3H),1.06(s,3H),0.96(s,3H);13C NMR(151MHz,CDCl3)δ:176.96,170.02,169.58,140.71,137.14,134.74,129.93,129.62,127.70,126.55,123.52,114.04,63.76,49.11,46.06,45.57,37.66,34.30,28.86,28.81,25.36,24.81,24.23,23.06。
实施例8
3-(3′-甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物8)的制备:
制备方法同实施例1,以间甲基肉桂酰氯替换对氟肉桂酰氯,产物3-(3′-甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率79.3%。1H NMR(600MHz,CDCl3)δ:7.66(d,J=15.6Hz,1H),7.39(s,1H),7.34(d,J=7.9Hz,1H),7.29(s,1H),7.23(t,J=7.6Hz,1H),7.15(d,J=7.6Hz,1H),5.75(s,1H),4.11(d,J=14.5Hz,1H),3.56(d,J=14.5Hz,1H),2.35(s,3H),1.95(s,1H),1.82-1.93(m,1H),1.77-1.81(m,1H),1.71(d,J=10.1,1H),1.52-1.57(m,1H),1.39(d,J=10.1Hz,1H),1.27-1.33(m,1H),1.16(s,3H),1.09(s,3H),1.05(s,3H),0.95(s,3H);13C NMR(151MHz,CDCl3)δ:184.68,176.53,170.01,142.95,138.31,135.20,130.68,128.59,128.56,125.74,121.81,114.21,63.71,49.13,46.07,45.48,37.68,34.33,28.89,28.77,25.37,24.81,24.21,23.10,21.31。
实施例9
3-(2′-甲氧基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物9)的制备:
制备方法同实施例1,以间甲氧基肉桂酰氯替换对氟肉桂酰氯,产物3-(2′-甲氧基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率75.9%。1H NMR(600MHz,CDCl3)δ:8.08(d,J=15.7Hz,1H),7.61(d,J=7.7Hz,1H),7.35(d,J=15.8Hz,1H),7.32(d,J=6.9Hz,1H),6.94(t,J=7.5Hz,1H),6.90(d,J=8.3Hz,1H),5.76(s,1H),4.12(d,J=14.4Hz,1H),3.89(s,3H),3.59(d,J=14.4Hz,1H),1.97(s,1H),1.89-1.94(m,1H),1.79-1.84(m,1H),1.73(d,J=10.2Hz,1H),1.53-1.59(m,1H),1.41(d,J=10.1Hz,1H),1.30-1.34(m,1H),1.18(s,3H),1.11(s,3H),1.07(s,3H),0.98(s,3H);13C NMR(151MHz,CDCl3)δ:176.14,170.34,169.94,158.24,137.93,131.04,128.50,124.35,122.24,120.58,114.31,111.05,63.67,55.53,49.17,46.07,45.41,37.70,34.35,28.92,28.72,25.38,24.82,24.17,23.14。
实施例10
3-(3′-三氟甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物10)的制备:
制备方法同实施例1,以间三氟甲基肉桂酰氯替换对氟肉桂酰氯,产物3-(3′-三氟甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率74.5%。1H NMR(600MHz,CDCl3)δ:7.81(s,1H),7.74(d,J=8.0Hz,1H),7.68(d,J=15.6Hz,1H),7.61(d,J=7.8Hz,1H),7.50(t,J=7.8Hz,1H),7.34(d,J=15.6Hz,1H),5.78(s,1H),4.15(d,J=14.5Hz,1H),3.59(d,J=14.4Hz,1H),1.99(s,1H),1.92-1.97(m,1H),1.81-1.85(m,1H),1.75(d,J=10.2,1H),1.56-1.61(m,1H),1.43(d,J=10.2Hz,1H),1.31-1.36(m,1H),1.19(s,3H),1.12(s,3H),1.09(s,3H),0.99(s,3H);13C NMR(151MHz,CDCl3)δ:177.08,170.02,169.49,140.41,136.11,131.35,131.32,129.22,126.12,126.09,124.59,124.56,124.02,113.99,63.77,49.12,46.06,45.58,37.67,34.30,28.86,28.80,25.35,24.80,24.22,23.07。
实施例11
3-(2′-三氟甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物11)的制备:
制备方法同实施例1,以邻三氟甲基肉桂酰氯替换对氟肉桂酰氯,产物3-(2′-三氟甲基)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率72.8%。1H NMR(600MHz,CDCl3)δ:8.01(dd,J=15.4,2.3Hz,1H),7.83(d,J=7.8Hz,1H),7.69(d,J=7.9Hz,1H),7.55(t,J=7.6Hz,1H),7.45(t,J=7.6Hz,1H),7.28(d,J=15.3Hz,1H),5.76(s,1H),4.14(d,J=14.5Hz,1H),3.59(d,J=14.5Hz,1H),1.99(s,1H),1.92-1.96(m,1H),1.80-1.86(m,1H),1.74(d,J=10.2Hz,1H),1.56-1.61(m,1H),1.43(d,J=10.2Hz,1H),1.30-1.36(m,1H),1.19(s,3H),1.11(s,3H),1.09(s,3H),0.99(s,3H),0.85-0.93(m,1H);13C NMR(151MHz,CDCl3)δ:176.99,170.01,169.27,137.13,134.25,131.91,129.02,128.87,128.21,126.26,125.99,125.95,113.95,63.79,49.09,46.06,45.53,37.67,34.26,28.87,28.76,25.34,24.80,24.15,23.02。
实施例12
3-(4′-溴)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮(化合物12)的制备:
制备方法同实施例1,以对溴肉桂酰氯替换对氟肉桂酰氯,产物3-(4′-溴)肉桂酰基-5,5,9,9-四甲基-4,5,6,7,8,9-六氢-5a,8-桥亚甲基苯并[d]吖庚因-2(3H)-酮为白色固体粉末,收率71.3%。1H NMR(600MHz,CDCl3)δ:7.61(d,J=15.5Hz,1H),7.49(d,J=8.5Hz,2H),7.43(d,J=8.6Hz,2H),7.28(d,J=15.5Hz,1H),5.76(s,1H),4.13(d,J=14.4Hz,1H),3.57(d,J=14.5Hz,1H),1.98(s,1H),1.90-1.96(m,1H),1.79-1.84(m,1H),1.73(d,J=10.2Hz,1H),1.54-1.60(m,1H),1.42(d,J=10.2Hz,1H),1.29-1.36(m,1H),1.18(s,3H),1.11(s,3H),1.07(s,3H),0.97(s,3H);13C NMR(151MHz,CDCl3)δ:176.87,170.02,169.68,141.05,134.24,131.91,129.60,123.91,122.80,114.06,63.74,49.11,46.05,45.54,37.67,34.30,28.87,28.78,25.36,24.80,24.21,23.08。
实施例13
异长叶烯酮基己内酰胺衍生物(1-12)对人源乳腺癌细胞(MCF-7的抗肿瘤活性实验,具体步骤如下:
(1)样品配制:用减重法精确称取样品,溶于DMSO中,振荡器使其充分溶解后配置成50mmol/L的原液,将其分装保存。
(2)肿瘤细胞的培养传代:将冻存的肿瘤细胞于37℃的恒温水槽中快速解冻,转移到培养瓶中,加入培养液,置于培养箱(CO2浓度为5%,温度为37℃)培养。待细胞瓶中的细胞密度达到80%的密度的时候,移去细胞瓶中旧的培养基,用1×PBS缓冲液洗涤贴壁细胞,然后用500μL的0.5%胰蛋白酶放培养箱消化2min,加入3mL的培养基终止消化,用移液枪轻轻吹打至细胞为单个细胞,加入适量的新鲜培养基,将细胞液吹打成均匀的细胞悬浮液,分瓶,置于培养箱中培养。
(3)需测试的细胞培养:将生长期为对数生长的肿瘤细胞用消化胰酶消化,加入适量的DMEM血清培养基,血球计数板计数,取细胞悬液,将细胞悬液稀释成5×104个细胞/mL的细胞悬液,均匀吹打细胞悬液。在96孔培养板中每个孔加100μL/孔的细胞悬液,置于培养箱中培养24h,使细胞贴壁。然后,弃去96孔板中旧的培养基,将待测样品的药液与阳性对照样品的药液按所需的终浓度梯度(0、0.1、0.5、2.5、5、10、20和40μM)加药,每个浓度设置3个平行实验。将加完药液培养基的96孔板继续培养48h。
(4)MTT比色法测定细胞存活率:将上述96孔板细胞加10μL的MTT溶液,放入培养箱中孵育4h后,弃去液体,每个孔中加入100μLDMSO,避光振荡5min,在540nm波长下用酶标仪测每个孔的OD值。
Graphpad Prism 7软件处理所测得数据并计算细胞增殖的半数抑制浓度IC50。
表1异长叶烯酮基己内酰胺衍生物对人源乳腺癌细胞(MCF-7)的抗增殖活性
12个异长叶烯酮基己内酰胺衍生物的抗肿瘤活性如表1所示,结果表明化合物1-12对体外的乳腺癌肿瘤细胞株(MCF-7)都表现出良好的抑制活性;化合物2、4、5-10、12对MCF-7肿瘤细胞的ICs0均小于5μM;化合物2、8、9、10对MCF-7的抑制活性优于紫杉醇。当苯环上2、3、4位上为三氟甲基基团时,化合物活性较好,其中,化合物10对MCF-7的抑制活性最强,其IC50值为0.32μM,抑制活性优于紫杉醇。苯环3位取代和2位取代的化合物活性高于苯环上4位取代的化合物。
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010770691.9A CN111892539B (zh) | 2020-08-03 | 2020-08-03 | 异长叶烯酮基己内酰胺衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010770691.9A CN111892539B (zh) | 2020-08-03 | 2020-08-03 | 异长叶烯酮基己内酰胺衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111892539A CN111892539A (zh) | 2020-11-06 |
CN111892539B true CN111892539B (zh) | 2022-03-04 |
Family
ID=73183278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010770691.9A Expired - Fee Related CN111892539B (zh) | 2020-08-03 | 2020-08-03 | 异长叶烯酮基己内酰胺衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111892539B (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105669565B (zh) * | 2016-03-21 | 2017-07-11 | 南京林业大学 | 异长叶烷基嘧啶类化合物及其制备方法与应用 |
CN108947904B (zh) * | 2018-08-06 | 2021-09-10 | 上海康邦德生物医药有限公司 | 一种含有七元内酰胺环的化合物及其应用 |
-
2020
- 2020-08-03 CN CN202010770691.9A patent/CN111892539B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN111892539A (zh) | 2020-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108117507B (zh) | 一种氮杂螺环己二烯酮的合成方法和用途 | |
CN108640968A (zh) | 一种混源萜类化合物及其在制备抗炎药物中的用途 | |
CN111892539B (zh) | 异长叶烯酮基己内酰胺衍生物及其制备方法和应用 | |
CN113173963A (zh) | 一种抗肿瘤的白桦醇衍生物、制备方法及其应用 | |
CN108558986B (zh) | 含哌嗪结构的甘草次酸类衍生物及其制备方法与用途 | |
CN111518086A (zh) | 氧化吲哚-萘并呋喃衍生物及其制备方法、用途以及包含其的药物组合物、制剂 | |
CN107118212B (zh) | 1-吡啶-6-甲氧基-9-(3-碘苄)-β-咔啉、合成和应用 | |
CN106986854B (zh) | 一种没药烷倍半萜结构类似物及其制备方法与应用 | |
CN111892540B (zh) | 一种化合物及其制备方法和应用 | |
CN108329300B (zh) | 硝基苯并[d]氮杂*基喹唑啉类化合物及其制备方法和应用 | |
CN110511233B (zh) | 一种噻唑并[2,3-b]噁唑酮类化合物及其制备方法和用途 | |
CN109400595B (zh) | 一类含噻吩环的抗癌化合物 | |
CN107382944B (zh) | 一类具有抗肿瘤活性的香豆素棉酚衍生物及其合成方法 | |
CN111004145A (zh) | 一种手性光学酰胺取代的α,β-二氨基酸衍生物及其制备方法和应用 | |
CN113929669B (zh) | 一种新型橙皮素嘧啶腙衍生物及其制备方法和应用 | |
CN115368309A (zh) | 异长叶烷基双吡唑类衍生物及其制备方法和应用 | |
CN103819408B (zh) | 硝基咪唑衍生物及其制备方法和用途 | |
CN110684033B (zh) | 四氢呋喃二喹啉化合物及其合成方法和应用 | |
CN112375112B (zh) | 一种苯并咪唑衍生物bi361及其制备方法和应用 | |
CN110642821B (zh) | 酢浆草中一种化合物及其提取分离方法及应用 | |
CN116621812B (zh) | 四氢吲唑化合物、制备方法及其在治疗食管鳞癌中的应用 | |
CN116925029A (zh) | 香豆素-哌嗪-二硫代氨基甲酸酯杂化物及其制备方法和应用 | |
CN112250725B (zh) | 一种苯并咪唑衍生物bi345及其制备方法和应用 | |
CN114539282B (zh) | 一种具有抗骨质疏松功效的化合物及其制备方法和应用 | |
CN108078993B (zh) | 6-硝基喹唑啉类化合物在制备治疗肺癌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220304 |